Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | USP2 | O75604 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.76 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.76 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | VDR | P11473 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014063 | 1.00 | MAPT (0.81) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL22699678 | 0.92 | MAPT (0.83) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL4971166 | 0.92 | MAPT (0.83) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL18216458 | 0.91 | MAPT (0.81) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL2260486 | 0.91 | MAPT (0.81) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL23710355 | 0.91 | MAPT (0.81) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL5431048 | 0.91 | MAPT (0.81) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL17090568 | 0.91 | MAPT (0.69) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL5436906 | 0.90 | MAPT (0.80) | MAPTMEN1KMT2AUSP2MAPK1 | |
| SCHEMBL5531597 | 0.90 | MAPT (0.80) | MAPTMEN1KMT2AUSP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2020-03-19 | — | — | US | disclosed |
| US-10376533-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3090748-A1 | COMPOSITIONS COMPRISING NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | Spring Bank Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-1968612-B1 | DINUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-8404651-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404651-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120264709-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264709-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264709-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885 |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885 |
| US-10376533-B2 | Compositions and methods for treating viral infections | SLC10A1, HAVCR2, CYP3A43 | MAPT 42/4885MEN1 2479/4885KMT2A 2552/4885 |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | MAPT 42/4885MEN1 2479/4885KMT2A 2552/4885 |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885 |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885 |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | MAPT 4011/4885MEN1 3192/4885KMT2A 2964/4885 |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | MAPT 42/4885MEN1 2479/4885KMT2A 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.